Patrick O'Brien - 03 Jan 2024 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Footnote F1

Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Footnote F2

Partial disposition of RSUs to satisfy tax withholding obligations.

Footnote F3

The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $31.21 to $32.19, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

Footnote F4

Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.

Footnote F5

The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $32.22 to $32.91, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

Footnote F6

The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $33.10 to $33.76, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

Footnote F7

Represents shares underlying restricted stock units with a grant date 01/04/24, which will vest in four equal annual installments.

Footnote F8

The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $33.45 to $34.45, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

Footnote F9

The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $34.465 to $35.45, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

Footnote F10

The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $35.49 to $35.96, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.